WO2013088449A1 - Forme cristalline stable de febuxostat et procédé de préparation correspondant - Google Patents

Forme cristalline stable de febuxostat et procédé de préparation correspondant Download PDF

Info

Publication number
WO2013088449A1
WO2013088449A1 PCT/IN2011/000864 IN2011000864W WO2013088449A1 WO 2013088449 A1 WO2013088449 A1 WO 2013088449A1 IN 2011000864 W IN2011000864 W IN 2011000864W WO 2013088449 A1 WO2013088449 A1 WO 2013088449A1
Authority
WO
WIPO (PCT)
Prior art keywords
febuxostat
crystalline form
stable
depicted
preparation
Prior art date
Application number
PCT/IN2011/000864
Other languages
English (en)
Inventor
Amala Kishan Kompella
Venugopola Krishna GAMPA
Subhash KUSUMBA
Kala Satya Bhujanga Rao ADIBHATLA
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Limited filed Critical Natco Pharma Limited
Priority to PCT/IN2011/000864 priority Critical patent/WO2013088449A1/fr
Publication of WO2013088449A1 publication Critical patent/WO2013088449A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Definitions

  • Febuxostat(I) is approved under the trademark Uloric ® by the US Food and Drug Administration for the treatment hyperuricemia and gouty arthritis.
  • PCT publication no. WO 1992/109279 describes Febuxostat.
  • PCT publication no. WO 1999/065885, PCT publication no. WO 2003/082279, PCT publication no. WO 2008/067773, CN 100546985, CN 101 139325, CN 101085761 , CN 101412700, CN 101386605, CN 101648926, CN 101671314, CN 101684107 and Heterocycles, 47, 2, 857- 864 describe various crystalline forms of Febuxostat including forms A,B,C,D,G,H,I,J,K and M as well as an amorphous form.
  • the present invention relates to the solid state physical properties of Febuxostat, 2-[3- cyano : 4-(2-methylpropoxy) phenyl] -4-methylthiazole-5-carboxylic acid.
  • Important solid state properties of a pharmaceutical substance are its rate of dissolution in aqueous fluid.
  • the rate of dissolution of an active ingredient in a patient's stomach fluid may have therapeutic consequences because it imposes an upper limit on the rate at which an orally-administered active ingredient may reach the blood stream.
  • the solid state form of a compound may also affect its behavior on compaction and its storage stability.
  • the polymorphic form may give rise to thermal behavior different form that of the amorphous material (or) another polymorphic form.
  • Thermal behavior is measured in the laboratory by such techniques as capillary melting point, Thermo Gravimetric Analysis (TGA) and Differential Scanning Calorimetry (DSC), and may be used to distinguish some polymorphic forms from others.
  • TGA Thermo Gravimetric Analysis
  • DSC Differential Scanning Calorimetry
  • a particular polymorphic form may also give rise to distinct properties that may be detectable by X-Ray Powder Diffraction (XRPD) solid state 13 CNMR spectrometry and infrared spectrometry.
  • XRPD X-Ray Powder Diffraction
  • Novel FC-1 form of high HPLC purity (> 99.8%) can be prepared under certain specific conditions with improved physical properties such as greater stability and less hygroscopic etc thereby making it suitable for commercial pharmaceutical applications.
  • the novel FC- 1 form is not meta stable and is stable at room temperature and even at higher temperatures like 70°C.
  • FC- 1 form of Febuxostat is hither to not known and is a novel polymorphic form.
  • the form prepared by us now is also suitable for developing a pharmaceutical composition.
  • Such a pharmaceutical composition containing FC- 1 form is also not known earlier and is novel.
  • the present invention provides highly pure (> 99.8%) FC- 1 crystalline form of Febuxostat which is stable at room temperature and even at higher temperatures like 70°C and accelerated high humidity stress conditions having the XRD characteristics given in the Table-I.
  • a process for the preparation novel crystalline form FC- 1 of Febuxostat which is stable at room temperature and even at higher temperatures like 70°C and accelerated high humidity stress conditions, and having the characteristics given in Table 1 which comprises dissolving Febuxostat in solvents like tetrahydrofuran(THF), acetone clarifying the solution with activated carbon and adding the clear solution to an anti solvent like methanol and water at room temperature and maintaining the reaction mixture at room temperature for a period in the range of 3-6hours and, filtering to obtain the FC- 1 crystal form.
  • the crystal form FC-I of Febuxostat may also be obtained by crystallizing Febuxostat from solvent mixtures like methanol/n-butanol, methanol/ethyl
  • Fig. l of the drawings accompanying these specifications shows the X-Ray Powder Diffraction (XRPD) pattern which substantially depicts a typically pure sample of Febuxostat of FC- 1 form prepared by the process disclosed in the Example- 1 given below.
  • the 2 ⁇ values and intensities are tabulated in Table- 1 .
  • Table-2 shows the heat stability of FC- 1 form over the temperature range 70-75°C.
  • the FC-1 form is shown to be non-meta stable and stable when heated at 70°C for 40 hours.
  • Table-3 shows suitable ranges of active ingredients and excipients (weight %) and the preferred amounts for the present pharmaceutical formulations.
  • Table-4 shows the stability of FC- 1 form of Febuxostat formulation and API under accelerated stress conditions (45 ⁇ 2°C, 75 ⁇ 5% PvH, 6 months).
  • FC- 1 form of Febuxostat in API and formulation in accelerated high humidity stress conditions is thus established.
  • the details of the invention are provided in the examples given below which are provided to illustrate the invention only and therefore they should not be construed to limit the scope of the invention.
  • Ethyl 2-(3- cyano-4-isobutyloxyphenyl)-4-methylthiazole-5-carboxylate ( 17.0g, 0.045mol) was hydrolyzed using aqueous (4.0%) sodium hydroxide (4.08g, 0.102mol) solution in THF( 170ml)and methanol( 127ml). The reaction was performed at 60-65°C for 30minutes. After reaction completion water (340ml) was added to the reaction mixture at room temperature, which then was acidified to about pH 2-3 with IN HC1 (90ml). The precipitated febuxostat was separated by filtration to yield crude wet product (23g, purity by HPLC-99.55%).
  • the crude wet product was dissolved in THF(72ml) at 50-55°C.
  • Activated carbon(0.5) was charged to the clear solution and maintained at 50-55°C for 30minutes.
  • the reaction mass was filtered and washed with THF(29ml).
  • the filtrate was brought to room temperature and added slowly during one hour to the mixture of methanol( 17ml) and water( 100ml) and stirred for 6hours .
  • the product was filtered and washed with water(80ml) and vacuum dried at 60-65°C to yield Febuxostat ( 13g, 92%) of 99.92% HPLC purity.
  • the product was identified as polymorphic form FC- 1 by XRD, IR, DSC, TGA, crystal morphology ( Figures- 1 to 5).
  • Ethyl 2-(3- cyano-4-isobutyloxyphenyl)-4-methylthiazole-5-carboxylate (30. Og, 0.0788mol) was hydrolyzed using aqueous (4.0%) sodium hydroxide (7.2g, 0.180mol) solution in Acetone(350ml). The reaction was performed at 50°C for 60minutes. After completion of reaction, water (600ml) was added to the reaction mixture at room temperature, which then was acidified to about pH 2-3 with IN HC1 ( 150ml). The precipitated Febuxostat was separated by filtration to yield crude wet product(48g, purity by HPLC-99.57%). The crude wet product was dissolved in acetone(300ml) at 50-55°C.
  • Activated carbon(0.5) was charged to the clear solution and maintained at 50-55°C for 30minutes.
  • the reaction mass was filtered and washed with acetone(60ml). Filtrate was brought to room temperature and water(360ml)was added slowly during one hour .
  • the reaction mass was stirred for 6hours, filtered and washed with water( 150ml) . Filtered product was vacuum dried at 60-65°C to yield Febuxostat (22g, 88.3%) of 99.80% HPLC purity.
  • the product was identified as FC-1 by XRD, IR, DSC, TGA, crystal morphology.
  • Ethyl 2-(3- cyano-4-isobutyloxyphenyl)-4-methylthiazole-5-carboxylate (20. Og, 0.0525mol) was hydrolyzed using aqueous (4.0%) sodium hydroxide (4.8g, 0.120mol) solution in THF(200ml)and methanol( 150ml). The reaction was performed at 60-65°C for 30minutes. After completion of reaction water (400ml) was added to the reaction mixture at room temperature, which then was acidified to about pH 2-3 with IN HC1 ( 100ml). The precipitated Febuxostat was separated by filtration and dried at 60-65°C to yield crude product( 16g, purity by HPLC-99.5%).
  • the crude product was dissolved in a mixture of methanol(260ml)and n-butanol( 130ml) at 50-55°C.
  • Activated carbon(0.5) was charged to the clear solution and maintained at 50-55°C for 30minutes.
  • the reaction mass was filtered and washed with methanol(40ml). Filtrate was brought to room temperature and cooled to 0-5°C for 3hours, filtered and washed with chilled methanol(40ml) . Filtered product was vacuum dried at 60-65°C to yield Febuxostat (1 l g, 66%) of 99.8% HPLC purity.
  • the product was identified as FC- 1 by XRD, IR, DSC, TGA, crystal morphology.
  • Ethyl 2-(3- cyano-4-isobutyloxyphenyl)-4-methylthiazole-5-carboxylate (20. Og, 0.0525mol) was hydrolyzed using aqueous (4.0%) sodium hydroxide (4.8g, 0.120mol) solution in THF(200ml)and methanol( 150ml). The reaction was performed at 60-65°C for 30minutes. After completion of reaction water (400ml) was added to the reaction mixture at room temperature, which then was acidified to about pH 2-3 with IN HCl (100ml). The precipitated Febuxostat was separated by filtration and dried at 60-65°C to yield crude product( 16g, purity by HPLC-99.5%).
  • Ethyl 2-(3- cyano-4-isobutyloxyphenyl)-4-methylthiazole-5-carboxylate (20. Og, 0.0525mol) was hydrolyzed using aqueous (4.0%) sodium hydroxide (4.8g, 0.120mol) solution in THF(200ml)and methanol( 150ml). The reaction was performed at 60-65°C for 30minutes. After completion of reaction water (400ml) was added to the reaction mixture at room temperature, which then was acidified to about pH 2-3 with I N HCl ( 100ml). The precipitated Febuxostat was separated by filtration and dried at
  • FC- 1 polymorphic form of Febuxostat is stable at room temperature and at accelerated high humidity stress conditions (40oC, 75% RH, 6months).
  • the novel FC- 1 polymorph of febuxostat is stable even at high temperatures like 70°C (40hours).
  • the novel FC- 1 form prepared is suitable for pharmaceutical applications.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur une nouvelle forme polymorphe FC-1 stable du febuxostat [l'acide 2-[3-cyano-4-(2-méthylpropoxy)phényl]-4-méthyl-5-thiazole carboxylique]. L'invention porte également sur un procédé pour la préparation de la nouvelle forme polymorphe FC-1 stable ayant une pureté par HPLC > 99,8 %.
PCT/IN2011/000864 2011-12-16 2011-12-16 Forme cristalline stable de febuxostat et procédé de préparation correspondant WO2013088449A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2011/000864 WO2013088449A1 (fr) 2011-12-16 2011-12-16 Forme cristalline stable de febuxostat et procédé de préparation correspondant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2011/000864 WO2013088449A1 (fr) 2011-12-16 2011-12-16 Forme cristalline stable de febuxostat et procédé de préparation correspondant

Publications (1)

Publication Number Publication Date
WO2013088449A1 true WO2013088449A1 (fr) 2013-06-20

Family

ID=45888449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000864 WO2013088449A1 (fr) 2011-12-16 2011-12-16 Forme cristalline stable de febuxostat et procédé de préparation correspondant

Country Status (1)

Country Link
WO (1) WO2013088449A1 (fr)

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009279A1 (fr) 1990-11-30 1992-06-11 Teijin Limited Derive de 2-arylthiazole et composition pharmaceutique contenant ce derive
WO1999065885A1 (fr) 1998-06-19 1999-12-23 Teijin Limited Modifications polymorphes de 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-acide carboxylique et procedes de preparation associes
WO2003082279A1 (fr) 2002-03-28 2003-10-09 Teijin Limited Preparation solide contenant une forme monocristalline
CN101085761A (zh) 2007-06-29 2007-12-12 上海华拓医药科技发展股份有限公司 非布他特微晶及其组合物
CN101139325A (zh) 2006-09-07 2008-03-12 上海医药工业研究院 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法
WO2008067773A1 (fr) 2006-12-07 2008-06-12 Chongqing Pharmaceutical Research Institute Co., Ltd. Nouveaux types de cristaux de febuxostat et procédés de préparation de ceux-ci
CN101386605A (zh) 2008-10-23 2009-03-18 中国科学院上海药物研究所 非布司他新型晶体及其制备方法
CN101412700A (zh) 2007-10-19 2009-04-22 上海医药工业研究院 非布司他的晶型及其制备方法
CN101648926A (zh) 2009-07-09 2010-02-17 石药集团欧意药业有限公司 一种非布司他晶型及其制备方法
CN101671314A (zh) 2009-09-17 2010-03-17 中国药科大学 一种非布索坦的晶型体及制备方法
CN101684107A (zh) 2008-09-26 2010-03-31 上海优拓医药科技有限公司 非布索坦的新晶型及其制备方法
WO2010144685A1 (fr) * 2009-06-10 2010-12-16 Teva Pharmaceutical Industries Ltd. Forme cristalline du febuxostat
WO2011080651A2 (fr) * 2009-12-31 2011-07-07 Ranbaxy Laboratories Limited Formes polymorphes de fébuxostat

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009279A1 (fr) 1990-11-30 1992-06-11 Teijin Limited Derive de 2-arylthiazole et composition pharmaceutique contenant ce derive
WO1999065885A1 (fr) 1998-06-19 1999-12-23 Teijin Limited Modifications polymorphes de 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-acide carboxylique et procedes de preparation associes
EP1020454A1 (fr) * 1998-06-19 2000-07-19 Teijin Limited Modifications polymorphes de 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-acide carboxylique et procedes de preparation associes
WO2003082279A1 (fr) 2002-03-28 2003-10-09 Teijin Limited Preparation solide contenant une forme monocristalline
CN101139325A (zh) 2006-09-07 2008-03-12 上海医药工业研究院 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法
WO2008067773A1 (fr) 2006-12-07 2008-06-12 Chongqing Pharmaceutical Research Institute Co., Ltd. Nouveaux types de cristaux de febuxostat et procédés de préparation de ceux-ci
CN101085761A (zh) 2007-06-29 2007-12-12 上海华拓医药科技发展股份有限公司 非布他特微晶及其组合物
CN100546985C (zh) 2007-06-29 2009-10-07 上海华拓医药科技发展股份有限公司 非布他特微晶及其组合物
CN101412700A (zh) 2007-10-19 2009-04-22 上海医药工业研究院 非布司他的晶型及其制备方法
CN101684107A (zh) 2008-09-26 2010-03-31 上海优拓医药科技有限公司 非布索坦的新晶型及其制备方法
CN101386605A (zh) 2008-10-23 2009-03-18 中国科学院上海药物研究所 非布司他新型晶体及其制备方法
WO2010144685A1 (fr) * 2009-06-10 2010-12-16 Teva Pharmaceutical Industries Ltd. Forme cristalline du febuxostat
CN101648926A (zh) 2009-07-09 2010-02-17 石药集团欧意药业有限公司 一种非布司他晶型及其制备方法
CN101671314A (zh) 2009-09-17 2010-03-17 中国药科大学 一种非布索坦的晶型体及制备方法
WO2011080651A2 (fr) * 2009-12-31 2011-07-07 Ranbaxy Laboratories Limited Formes polymorphes de fébuxostat

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954, ISSN: 0340-1022, ISBN: 978-3-540-36760-4, DOI: 10.1007/3-540-69178-2_5 *
HETEROCYCLES, vol. 47, no. 2, pages 857 - 864

Similar Documents

Publication Publication Date Title
US8048883B2 (en) Polymorphic form of imatinib mesylate and a process for its preparation
US11111223B2 (en) Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
US8609856B2 (en) Crystalline forms of Febuxostat
US10273262B2 (en) Crystalline form A of obeticholic acid and preparation method thereof
US20060223816A1 (en) Imatinib mesylate alpha form and production process therefor
WO2012027543A1 (fr) Formes solides de dabigatran étexilate et de dabigatran étexilate mésylate et leurs méthodes de préparation
US20090298947A1 (en) Polymorphic and amorphous forms of lacosamide and amorphous compositions
WO2010062715A2 (fr) Polymorphes de dasatinib et leur procédé de préparation
JP2011512396A (ja) 新規な多形およびその調製方法
US8252805B2 (en) Forms of lapatinib ditosylate and processes for preparation thereof
TW201200511A (en) Crystalline salts of a potent HCV inhibitor
KR20170057441A (ko) Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법
TWI801421B (zh) 結晶
JP2016536321A (ja) カナグリフロジンのｂ形結晶、ｃ形およびｄ形
WO2018015974A1 (fr) Formes polymorphes de sélexipag et dispersion solide amorphe de sélexipag
US8962833B2 (en) Salts of raltegravir
WO2013088449A1 (fr) Forme cristalline stable de febuxostat et procédé de préparation correspondant
CA2980224C (fr) Forme cristalline de ahu377, procede de preparation et utilisation de cette derniere
WO2017206827A1 (fr) Forme cristalline de l'inhibiteur du cotransporteur de sodium-glucose de type 2
EP2393786A2 (fr) Nouveaux polymorphes du lopinavir
TWI777380B (zh) 2-吲哚啉螺環酮類化合物之結晶形式
CN113149998B (zh) 2-吲哚啉螺环酮类化合物或其盐、溶剂合物的无定形形式或结晶形式
WO2017098336A1 (fr) Nouveaux polymorphes de vemurafenib, leur procédé de préparation, et composition pharmaceutique les contenant
WO2019092752A2 (fr) Nouveau sel de lénalidomide et ses formes polymorphes
WO2018001997A1 (fr) Sel calcique cristallin de l'acide (s)-2-(diphénylacétyl)-1,2,3,4-tétrahydro-6-méthoxy-5-(phénylméthoxy)-3-isoquinoléine-carboxylique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11827792

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11827792

Country of ref document: EP

Kind code of ref document: A1